Open Access
Subscription Access
Aberration in NFkB–IkB Binding May Cause Two States of NFkB Activity
NFkB activation is involved in cell survival and aberration of NFkB signalling is found in cancer. IkB is an inhibitor that sequesters NFkB in the cytoplasm. By mathematical modelling, we predict that under an aberrant condition in which IkB does not bind to NFkB, there exist two states of NFkB activity: a constitutive activity state for any positive value of the stimulus and a zero activity state for no stimulus. Further, under the assumption that NIK can be activated by TAB1–pTAK1, we predict that TAB1 has a role in the basal activity of NFkB. Thus, we predict the importance of TAB1 and IkB in NFkB activation. Our prediction may have implication for cell survival and cancer.
Keywords
Basal Activity, Cancer, Cell Survival, Constitutive Activation, Protein Complex.
User
Font Size
Information
- Singh, R., Model predicts that MKP1 and TAB1 regulate p38 alpha nuclear pulse and its basal activity through positive and negative feedback loops in response to IL-1. PLoS ONE, 2016, 11, e0157572; doi:10.1371/journal.pone.0157572.
- Ninomiya-Tsuji, J. et al., The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature, 1999, 398, 252–256; doi:10.1038/18465.
- Takaesu, G. et al., TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol. Cell, 2000, 5, 649–658.
- Sakurai, H., Miyoshi, H., Mizukami, J. and Sugita, T., Phosphorylationdependent activation of TAK1 mitogen-activated protein kinase kinase kinase by TAB1. FEBS Lett., 2000, 474, 141–145; doi:10.1016/S0014-5793(00)01588-X.
- Shibuya, H. et al., TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science, 1996, 272, 1179–1182.
- Wang, C. et al., TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature, 2001, 412, 346–351; doi:10.1038/35085597.
- Shim, J. H. et al., TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev., 2005, 19, 2668–2681; doi:10.1101/gad.1360605.
- Karin, M., How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene, 1999, 18, 6867–6874; doi: 10.1038/sj.onc.1203219.
- Rayet, B. and Gelinas, C., Aberrant rel/nfkb genes and activity in human cancer. Oncogene, 1999, 18, 6938–6947; doi:10.1038/sj.onc.1203221.
- Barakat, A. F., Elson, C. J. and Westacott, C. I., Susceptibility to physiological concentrations of IL-1beta varies in cartilage at different anatomical locations on human osteoarthritic knee joints. Osteoarthritis Cartilage, 2002, 10, 264–269; doi:10.1053/joca.2002.0515.
- Rasmussen, M. K. et al., IL-8 and p53 are inversely regulated through JNK, p38 and NF-kappaB p65 in HepG2 cells during an inflammatory response. Inflamm. Research: Off. J. Eur. Histamine Res. Soc., 2008, 57, 329–339; doi:10.1007/s00011-007-7220-1.
- Moynagh, P. N., Williams, D. C. and O’Neill, L. A., Interleukin-1 activates transcription factor NF kappa B in glial cells. Biochem. J., 1993, 294(Pt 2), 343–347.
- Li, W., Tan, D., Zenali, M. J. and Brown, R. E., Constitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma. Int. J. Clin. Exp. Pathol., 2009, 3, 238–243.
- Nagel, D., Vincendeau, M., Eitelhuber, A. C. and Krappmann, D., Mechanisms and consequences of constitutive NF-kappaB activation in B-cell lymphoid malignancies. Oncogene, 2014, 33, 5655–5665; doi:10.1038/onc.2013.565.
- Neil, J. R. and Schiemann, W. P., Altered TAB1 : I kappaB kinase interaction promotes transforming growth factor beta-mediated nuclear factor-kappaB activation during breast cancer progression. Cancer Res., 2008, 68, 1462–1470; doi:10.1158/0008-5472.CAN-07-3094.
- Lu, M. et al., XIAP induces NF-kappaB activation via the BIR1/TAB1 interaction and BIR1 dimerization. Mol. Cell, 2007, 26, 689–702; doi:10.1016/j.molcel.2007.05.006.
- Tak, P. P. and Firestein, G. S., NF-kappaB: a key role in inflammatory diseases. J. Clin. Invest., 2001, 107, 7–11; doi:10.1172/JCI11830.
- Baker, R. G., Hayden, M. S. and Ghosh, S., NF-kappaB, inflammation, and metabolic disease. Cell Metab., 2011, 13, 11–22; doi:10.1016/j.cmet.2010.12.008.
- O’Sullivan, B., Thompson, A. and Thomas, R., NF-kappa B as a therapeutic target in autoimmune disease. Expert Opin. Therap. Targets, 2007, 11, 111–122; doi:10.1517/14728222.11.2.111.
- Karin, M., NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harbor Perspect. Biol., 2009, 1, a000141; doi:10.1101/cshperspect.a000141.
- Wu, B. Y., Woffendin, C., Duckett, C. S., Ohno, T. and Nabel, G. J., Regulation of human retroviral latency by the NF-kappa B/I kappa B family: inhibition of human immunodeficiency virus replication by I kappa B through a Rev-dependent mechanism. Proc. Natl. Acad. Sci. USA, 1995, 92, 1480–1484.
- Zhao, Y., Krishnamurthy, B., Mollah, Z. U., Kay, T. W. and Thomas, H. E., NF-kappaB in type 1 diabetes. Inflamm. Allergy Drug Targets, 2011, 10, 208–217.
Abstract Views: 375
PDF Views: 119